Nov 25 2009
Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML). Additionally, non-clinical data will be presented evaluating the effect of AC220 monotherapy and in combination with chemotherapy.
"AML continues to be a disease with a significant unmet medical need and new therapies are urgently needed," said M. Scott Salka, Chief Executive Officer of Ambit Biosciences. "The Phase I clinical data we've seen for AC220 in AML are extremely encouraging and supports the further development of this highly selective second-generation FLT3 inhibitor."
Data Highlights for AC220 include:
ORAL PRESENTATIONS
Abstract #636
AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study
Presented by: Jorge Cortes, MD
Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II
Date: Monday, December 7, 2009, 5:45pm (session: 4:30 - 6:00pm), Morial Convention Center Room 343-345
POSTER PRESENTATIONS
Abstract# 2053
AC220 - A FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration
Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II
Sunday, December 6, 2009, 6:00 - 8:00pm, Hall E, Poster Board II-45
Abstract#: 2052
AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenograft
Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II
Sunday, December 6, 2009, 6:00 PM - 8:00 PM, Hall E, Poster Board II-44
Source:
Ambit Biosciences Corporation
Scientists develop a marker for therapy response in acute myeloid leukemia